arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Rezolute, Inc.

RZLT
$4.67 ▼ -0.03 (-0.53%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
65 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

Rezolute, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $485.9M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -11.7%
FCF / Share $-0.13
Trailing P/E
Price / Book 3.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-16.17M
↑ +14.5%
FCF / Share Free cash flow per share
$-0.13
↑ +32.6%
Long-Term Debt Long-term obligations
$14.29M
↑ +0.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
18
Cash Quality
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 65 quarters